Efficacy of the Hsp90 Inhibitors in Prostate Cancer Therapy
Journal Title: Journal of Urology & Nephrology - Year 2014, Vol 1, Issue 1
Abstract
Prostate cancer is a disease of aging and the second leading cause of death in men in the United States. A distinctive characteristic of prostate tumors is their dependence on androgen for development, growth and survival. The molecular chaperone Heat Shock Protein-90 (Hsp90) is involved in the stability of a number of protein targets including androgen receptor (AR). Preclinical data demonstrates Hsp90 inhibition to be an effective therapy for inhibiting prostate cancer cells in culture as well as in animal xenograft models. Two newgeneration Hsp90 inhibitors, ganetespib and AT13387, are currently being evaluated as single or combinational therapies in the clinic for castrate resistant prostate cancer (CRPC). While clinical signs of antitumor activity have been observed with new-generation HSP90 inhibitors, these drugs are likely to be most effective when used as part of combination treatments. This review highlights how inhibition of Hsp90 combined with specific secondary targets including Wee1, Hsp27, ERK and mTOR displays enhanced inhibitory effects in pre-clinical models. One clinical benefit of co-inhibition is the targeting of multiple signaling pathways. In addition, the variety of proposed combination therapies allows for latitude in selecting a secondary target, potentially tailoring therapies to specific patient populations.
Authors and Affiliations
Mehdi Mollapour
Keywords
Related Articles
- EP ID EP207434
- DOI 10.13188/2380-0585
- Views 156
- Downloads 0
Efficacy of the Hsp90 Inhibitors in Prostate Cancer Therapy
Prostate cancer is a disease of aging and the second leading cause of death in men in the United States. A distinctive characteristic of prostate tumors is their dependence on androgen for development, growth and surviva...
Future Applications of Intravesical SCL Gene Transfer for the Treatment of Diabetic Neurogenic Bladder
Diabetic cystopathy, a complication of diabetes affecting the bladder, is mainly characterized as reduced contractility of the detrusor and increased post-voiding residual volume, which is induced by the reduction of the...
Bid Cleavage and TRAIL Sensitivity in Urothelial Cell Carcinoma of the Bladder
opensity to recur after resection. Intravesical bacillus calmetteguerin (BCG) therapy significantly reduces recurrence of UCCB, and response to BCG therapy is believed to be mediated by tumor necrosis factor related apop...
Bacterial Ecology of Peritonitis in a Sub-Saharan Peritoneal Dialysis Unit
Introduction: Peritonitis is a common and serious complication of Peritoneal Dialysis (PD). Peritonitis is a major cause of PD technique failure and conversion to long-term hemodialysis. After acquiring 10 years of exper...
Arterial Calcification in Chronic Kidney Disease: Whom? When? and How to Handle?
Chronic kidney disease (CKD) patients have the highest mortality rate compared to other chronic diseases. Cardiovascular events account for up to 60% of the mortalities, with cardiovascular calcifications affecting the m...